Acute Stroke Unit, Division of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary, Glasgow, UK.
Diabetes Care. 2009 Jan;32(1):135-7. doi: 10.2337/dc08-1179. Epub 2008 Oct 22.
Type 2 diabetes increases risk of stroke, perhaps because of impaired cerebrovascular basal nitric oxide (NO) activity. We investigated whether this activity is improved by a 2-week course of the xanthine oxidase inhibitor allopurinol.
We performed a randomized, double-blind, placebo-controlled crossover study. We measured the response to infusion of NG-monomethyl-L-arginine (l-NMMA) in males with type 2 diabetes before and after allopurinol or placebo. The primary end point was the change in internal carotid artery flow following L-NMMA infusion, expressed as the area under the flow-per-time curve.
We enrolled 14 participants. Allopurinol improved responses to L-NMMA when compared with responses associated with placebo (P = 0.032; median reduction in internal carotid artery flow following L-NMMA of 3,144 ml [95% CI 375-7,143]).
Xanthine oxidase inhibition with allopurinol appears to improve cerebral NO bioavailability, as evidenced by a greater response to infusion of L-NMMA.
2 型糖尿病会增加中风的风险，这可能是由于脑血管基底一氧化氮（NO）活性受损所致。我们研究了黄嘌呤氧化酶抑制剂别嘌醇是否能改善这种活性。
我们进行了一项随机、双盲、安慰剂对照的交叉研究。我们在 2 型糖尿病男性患者中，在使用别嘌醇或安慰剂之前和之后，测量了 NG-单甲基-L-精氨酸（l-NMMA）输注后的颈内动脉血流反应。主要终点是 l-NMMA 输注后颈内动脉血流的变化，用血流-时间曲线下面积表示。
我们纳入了 14 名参与者。与安慰剂相比，别嘌醇改善了对 l-NMMA 的反应（P=0.032；l-NMMA 后颈内动脉血流减少中位数为 3144ml[95%CI 375-7143]）。
黄嘌呤氧化酶抑制作用别嘌醇似乎可以改善脑内 NO 的生物利用度，这可以从 l-NMMA 输注后更大的反应中得到证明。
